BGNE Aug 2024 175.000 call
| Previous Close | 15.00 |
| Open | 15.00 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 175.00 |
| Expire Date | 2024-08-16 |
| Day's Range | 15.00 - 15.00 |
| Contract Range | N/A |
| Volume | |
| Open Interest | N/A |
Business WireBRUKINSA® Data at ASCO Underscore Differentiated Clinical Profile for Treatment of CLL and SLL
SAN MATEO, Calif., May 24, 2024--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation of new analyses for BRUKINSA® (zanubrutinib) at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 31 - June 4, 2024. The presentations highlight analyses of the efficacy and safety of BRUKINSA compared to other Bruton’s tyrosine kinase inhibitors (BTKis) used to treat chronic lymphocytic leukemia (CLL) and small lymphoc
ZacksBeiGene's (BGNE) Shares Surge 32% in a Month: Here's Why
Beigene's (BGNE) shares surge 32% in a month due to the label expansion of one of its key oncology drugs, Tevimbra, to treat three NSCLC indications, including first- and second-line use, in the EU.
Business WireBeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024
SAN MATEO, Calif., May 14, 2024--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will share new data from its hematology portfolio and pipeline at the European Hematology Association 2024 Hybrid Congress (EHA2024) in Madrid, Spain, June 13-16, 2024. BeiGene has 28 abstracts accepted at EHA2024, with four scheduled for oral presentations.
